Articles

Whole-genome sequencing (WGS) has traditionally been an important tool in nonclinical research. Recently, however, the potential clinical value of the technique was demonstrated in a patient with acute promyelocytic leukemia (APL) that was hard to identify (Welch JS, et al. JAMA. 2011;305: 1577-1584).

Results of a phase 3 trial comparing that drug with the investigational agent vemurafenib show promise for patients with BRAF V600E mutation (Chapman PB, et al. N Engl JMed. 2011; 364:2507-2516).

Black women who undergo mastectomy or lumpectomy for advanced breast cancer have shorter survival duration than their white, Hispanic, and Asian counterparts, regardless of whether they undergo radiation therapy after the procedure, according to a new study (Martinez SR, et al. Cancer. Epub ahead of print. June 20, 2011).

A new large clinical trial funded by the National Cancer Institute has demonstrated the best approach to therapy for men with intermediaterisk, early-stage prostate cancer that can prolong survival.

The FDA has issued a warning to healthcare providers against substituting breast thermography formammography in screening for breast cancer.

As we move forward in the scheme of healthcare reform, we are being directed toward an integrated care model, one with high quality and economic efficiency. Recently, a model known as an accountable care organization (ACO) was introduced by the US Department of Health and Human Services in the form of a proposed rule open for public comment.

Chicago, IL—Nearly 2% of patients with cancermay file for personal bankruptcy 5 years after their diagnosis, according to researchers from Fred Hutchinson Cancer Research Center in Seattle who presented their data at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

Upper GI Malignancies” was a plenary session at ASCO 2011, with 2 experts discussing whether results of recent clinical trials of targeted agents are clinically meaningful or just statistically positive, and what is the value of the enormous amount of money spent in treating noncolorectal gastrointestinal (GI) cancer.